Market Overview

UPDATE: Bank Of America Reiterates On McKesson Ahead Of 4Q14 EPS

Share:
Related MCK
Morgan Stanley's Top 15 'Vintage Values' Stock Picks For 2016
Opposing Views For Rite Aid: Will Earnings Rise Or Fall?
Will McKesson (MCK) Keep the Earnings Streak Alive? - Analyst Blog (Zacks)

In a report published Tuesday, Bank of America analyst Robert M. Willoughby reiterated an Underperform rating on McKesson (NYSE: MCK), and raised the price target from $160.00 to $165.00.

In the report, Bank of America noted, “Rebounding profitability in MCK's core drug wholesaling operations, traction for its ancillary franchises, and capital deployment initiatives should drive industry-leading earnings growth over a leaner infrastructure. However, at valuation highs following the announcement of its Celesio acquisition, we see more attractive investment opportunities elsewhere.”

McKesson closed on Monday at $174.23.

Latest Ratings for MCK

DateFirmActionFromTo
May 2015BairdMaintainsOutperform
May 2015BarclaysMaintainsOverweight
Mar 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for MCK
View the Latest Analyst Ratings

Posted-In: Bank of America Robert M. WilloughbyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MCK)

Get Benzinga's Newsletters